Skip to main content

Table 3 Phase 3 studies of PARP inhibitors for maintenance therapy in patients with platinum-sensitive ovarian cancer

From: Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?

 

Prior lines of chemotherapy

Inclusion biomarkers

Median PFS, months

HR for PFS (95% CI)

P value

Active therapy

Placebo

Niraparib Monotherapy

 NOVA [38]

≥2

None

Patients stratified according to gBRCA status and HRD score

gBRCA: 21.0

5.5

0.27 (0.17–0.41)

<0.001

Non-gBRCA: 9.3

3.9

0.45 (0.34–0.61)

<0.001

HRD-positive: 12.9

3.8

0.38 (0.24–0.59)

<0.001

HRD-negative: 6.9

3.8

0.58 (0.36–0.92)

0.02

Olaparib Monotherapy

 SOLO-2 [39]

≥2

BRCA1/2 mutation

30.2

5.5

0.25 (0.18–0.35)

<0.001

Rucaparib Monotherapy

 ARIEL3 [45, 46]

≥3a

None

BRCA mutation: 16.6

HRD-positive: 13.6

ITT population: 10.8

5.4

5.4

5.4

0.23

0.32

0.36

<0.001

<0.001

<0.001

  1. CI confidence interval, gBRCA germline BRCA mutation, HR hazard ratio, HRD homologous recombination deficiency, ITT intent-to treat, PARP poly (ADP-ribose) polymerase, PFS progression-free survival
  2. aReceived ≥2 prior platinum-based treatment regimens including platinum based regimen and no more than 1 non-platinum chemotherapy regimen